Tevogen Bio

TVGNPhase 1

New Jersey, United Statestevogen.com

Tevogen Bio is a clinical-stage specialty immunotherapy company leveraging its patented ExacTcell technology to harness CD8+ cytotoxic T lymphocytes for the development of allogeneic, precision T cell therapies. Its lead candidate, TVGN-489, is in clinical development for COVID-19, with a pipeline extending to oncology and neurology. The company's vision centers on affordability and broad patient access, supported by a scalable manufacturing process and an AI-driven predictive technology arm, Tevogen.AI.

Market Cap

$21.1M

Focus

Cell & Gene Therapy

TVGN · Stock Price

USD 5.22493.28 (-98.95%)

Historical price data

AI Company Overview

Technology Platform

The ExacTcell platform selects and expands naturally occurring, genetically unmodified cytotoxic T lymphocytes (CTLs) to create off-the-shelf, precision T cell therapies that target disease-specific antigens presented by single HLA molecules.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
Cytotoxic T Lymphocytes	Covid19	Phase 1

Opportunities

The primary opportunity lies in validating the ExacTcell platform in COVID-19, which could unlock its application in larger oncology and neurology markets.

Successfully delivering on the promise of an affordable, off-the-shelf, precision T cell therapy could capture significant market share in the high-value but cost-burdened cell therapy sector.

Risk Factors

Key risks include early-stage clinical failure of the lead candidate, the unproven nature of the platform at scale, intense competition in target markets, and the constant need for capital funding inherent to pre-revenue biotech companies.

Competitive Landscape

Tevogen competes with allogeneic cell therapy developers (e.g., Allogene, Atara) and COVID-19 therapeutic companies. Its main differentiation is the use of genetically unmodified, multi-antigen specific CTLs and a strategic focus on cost-effective, scalable manufacturing to enable broader patient access.